Aeglea BioTherapeutics Investor Presentation Deck

SPY002 summary 1000 LEAD CLONES ARE MONOMER AND TRIMER BINDERS WITH POTENCY DESIGNED TO BE SUPERIOR TO SELECT ANTIBODIES SPYRE HI HUDO- ONLY KNOWN EXTENDED HALF-LIFE TL1A ANTIBODY IN DEVELOPMENT DEVELOPING PATIENT SELECTION APPROACHES TO IDENTIFY RESPONDERS INTERIM PHASE 1 PK DATA EXPECTED 1H2025 26

View entire presentation